William Blair analyst Jason Ader maintained a Buy rating on Nutanix (NTNX – Research Report) today. The company’s shares closed yesterday at ...

Analysts at William Blair upped their FY2025 EPS estimates for Straumann in a report issued on Monday, February 24th. William Blair analyst B. Vazquez now forecasts that the company will post earnings ...

In a report released today, Ryan Daniels from William Blair maintained a Hold rating on Teladoc (TDOC – Research Report). The company’s shares ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Research analysts at William Blair increased their Q1 2025 earnings estimates for shares of Tactile Systems Technology in a note issued to investors on Monday, February 24th. William Blair analyst M.

It will invest in government debt from frontier markets countries across Asia, Latin Am, Eastern Europe, Middle East, Africa ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for CACI International (NYSE:CACI) from ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

The new fund will invest in a niche subset of emerging markets that are 'more challenging for investors to access' ...

Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the ...

Repligen Corp (NASDAQ:RGEN) released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago ...